How Cancer Patients use Hemp in Palliative Care

Introduction

Last Updated: 12/22/2025

Palliative care is a patient-centered approach focused on improving quality of life for individuals facing chronic or life-limiting conditions. Rather than targeting disease outcomes, palliative care emphasizes comfort, symptom management, emotional well-being, and support for both patients and caregivers. This holistic model integrates medical, psychological, and social considerations to align treatment decisions with individual values and care goals.

Over the years, plant-based medicines have played an increasingly visible role within palliative care frameworks, particularly as supportive options aimed at comfort, quality of life, and holistic well-being. Botanicals such as ginger and peppermint have long been used to support digestive comfort, while lavender and chamomile are commonly incorporated into palliative settings for their calming and relaxation-associated properties.

In recent years, hemp-derived preparations have increasingly entered palliative care discussions. Historically, Cannabis sativa has been used for medicinal purposes for centuries, with documented applications dating back to approximately 400 AD in regions such as China, India, and the Middle East where preparations from different parts of the plant were used as supportive medicine for several conditions.

Within scientific and clinical literature, cannabis has been explored across a wide range of supportive care applications. Research discussions have described its use in relation to physical symptoms such as discomfort and sleep disturbances, as well as psychological and emotional challenges, including mood changes and distress experienced by individuals with serious illnesses. In oncology settings in particular, cannabis has been studied as a potential adjunctive option addressing both physical and psychological symptom burdens, contributing to ongoing interest in its role within comprehensive palliative care frameworks. For the purpose of this article, we would look at the role of hemp in palliative care for cancer patients.

Hemp in palliative care for cancer patients

Palliative care in oncology is designed to address the complex physical, psychological, and psychosocial challenges experienced by individuals with cancer, independent of disease stage or prognosis. As part of this multidisciplinary approach, integrative strategies are increasingly evaluated for their potential to support patient comfort, quality of life, and individualized care goals. Within this context, hemp-derived preparations, particularly full-spectrum or whole-plant formulations, have emerged as a subject of scientific and clinical inquiry.

Full-spectrum hemp contains a range of naturally occurring cannabinoids, terpenes, and flavonoids, distinguishing it from isolated single-compound products. Existing literature has examined hemp-derived compounds in relation to supportive care considerations relevant to oncology palliative settings, including tolerability, patient-reported experiences, and alignment with holistic care.

How cancer patients use hemp

Cancer-Related Pain

Hemp-derived products, especially full-spectrum or whole-plant hemp formulations, have entered palliative care discussions as supportive, non-curative options. Hemp contains naturally occurring cannabinoids, terpenes, and flavonoids that interact with the body’s endogenous regulatory systems, including pathways involved in pain perception and stress response. Scientific interest in hemp is largely driven by its low-THC profile and its potential role within supportive care frameworks rather than as a primary pain intervention.

Current evidence specific to hemp in cancer-related pain remains limited, with much of the available research extrapolated from broader cannabinoid studies or observational reports.

A 2021 systematic review and meta-analysis of 32 randomized clinical trials involving 5,174 adults found that non-inhaled medical cannabis or cannabinoids produced small improvements in pain relief compared with placebo, including in studies involving cancer-related pain. Most interventions were administered orally, with follow-up ranging from 1 to 5.5 months. The analysis reported modest gains in pain reduction, physical functioning, and sleep quality, but no improvement in emotional, social, or role functioning. However, oral cannabis was also associated with a small increased risk of transient adverse effects, including dizziness, drowsiness, nausea, and mild cognitive impairment.

A 2017 systematic review examined evidence from randomized controlled trials and long-term observational studies on the use of cannabinoids in pain management and palliative medicine including cancer pain. From 750 publications, 11 systematic reviews of moderate to high methodological quality and three prospective observational studies were included. The analysis found limited evidence of benefit for cannabinoid formulations in neuropathic pain, while evidence was insufficient to support effectiveness for cancer-related pain or other pain conditions.

A 2020 preclinical study examining hemp-derived phytochemicals reported notable pain-modulating effects following the use of hemp essential oil rich in terpenes such as β-caryophyllene and α-humulene, particularly in animal models of neuropathic and chemotherapy-induced cancer pain.

Chemotherapy-Induced Nausea and Vomiting (CINV)

Nausea and vomiting, particularly chemotherapy-induced nausea and vomiting (CINV), are among the most burdensome symptoms for patients undergoing cancer treatment, sometimes leading to missed or discontinued therapies. Despite advances in standard antiemetic treatments, many patients continue to experience these symptoms and explore additional supportive options.

Cannabis- and hemp-derived medicines, including THC, THC:CBD extracts, and synthetic analogs such as nabilone and dronabinol, have been studied as potential adjuncts for CINV. Early trials from the 1970s and 1980s suggested oral or inhaled THC could reduce episodes of vomiting and nausea in some patients, though adverse effects such as somnolence, dizziness, mood changes, and reduced concentration were common. Later studies demonstrated that THC: CBD formulations could improve antiemetic outcomes, with some patients reporting fewer daily vomiting episodes and reduced nausea scores compared to placebo. For instance, a 2023 phase II/III randomized, placebo-controlled trial reported that 24% of patients receiving THC:CBD capsules experienced a complete response compared with 8% for placebo, highlighting their potential role in supportive care under careful clinical supervision.

A 2025 systematic review of 32 clinical studies concluded that cannabinoid‑based therapies, including oral THC:CBD, significantly improved control of CINV compared with placebo and outdated antiemetics in many trials, though heterogenous results and side effects were noted.

Appetite and Chemosensory Changes in Cancer

A double-blind, placebo-controlled pilot study of advanced cancer patients with poor appetite and chemosensory alterations found that oral THC (2.5 mg twice daily for 18 days) significantly improved patients’ perception of taste and smell compared with placebo. Patients treated with THC reported that food tasted better and had improved pre-meal appetite, and they consumed a greater proportion of calories as protein.

Research in patients with HIV/AIDS suggests cannabinoids may stabilize or increase weight and improve appetite in this population, highlighting potential differences in response compared with cancer patients. Additionally, preliminary evidence indicates THC may improve chemosensory perception, taste, and pre-meal appetite, with modest increases in protein intake.

Insomnia and Mood Disorders

Sleep disturbance and mood disorders are prevalent among patients with cancer and often arise from pain, treatment burden, psychological stress, and systemic inflammation.

Although most clinical trials have evaluated isolated cannabinoids or THC-dominant products, secondary findings from pain and quality-of-life studies suggest that multi-compound cannabinoid formulations may contribute to improvements in sleep continuity and reduced sleep disruption at low to moderate doses. Observational studies further indicate that patients using whole-plant cannabis preparations report faster sleep onset, improved sleep maintenance, and decreased reliance on conventional sleep medications, though these findings are limited by study design and prior cannabis exposure.

Safety, Tolerability of full-spectrum hemp in palliative care

Full-spectrum hemp products are generally regarded as well-tolerated when used responsibly, particularly when derived from organically cultivated hemp and manufactured under strict quality controls. The presence of multiple naturally occurring cannabinoids, terpenes, and flavonoids may allow for therapeutic effects at lower doses compared with isolated compounds, potentially reducing dose-related adverse events such as sedation or gastrointestinal discomfort. However, mild effects including drowsiness, dry mouth, dizziness, or transient cognitive changes have been reported, especially during initiation or dose escalation.

In palliative care populations, drug–herb interactions warrant careful consideration, as cannabinoids can influence cytochrome P450 enzymes involved in the metabolism of commonly prescribed oncology and supportive-care medications, including opioids, anticoagulants, antiemetics, and anxiolytics. While clinically significant interactions remain incompletely characterized, conservative dosing and close monitoring are recommended, particularly in patients receiving polypharmacy.

Given the heterogeneity of cancer-related symptoms and patient responses, individualized care and medical oversight are essential. Selection of high-quality, third-party–tested full-spectrum hemp products, gradual titration, and ongoing clinical evaluation support safe integration into palliative care while prioritizing patient comfort, function, and quality of life.

Choosing the Right Full-Spectrum Hemp Product in Palliative Care

Selecting an appropriate full-spectrum (whole-plant) hemp product in palliative settings requires careful attention to quality, composition, and formulation. Clinically appropriate products should be derived from organically grown hemp, extracted using solvent-free methods, and supported by independent third-party Certificates of Analysis (COAs) confirming cannabinoid content, terpene profile, and the absence of contaminants such as heavy metals, pesticides, and residual solvents. Equally important is a balanced phytochemical profile, as whole-plant formulations that preserve naturally occurring cannabinoids and calming terpenes may better support rest, relaxation, and overall comfort through synergistic effects.

Products such as Active-Spectrum Rest & Relax Tincture exemplify this approach by maintaining the integrity of the hemp plant while emphasizing compounds commonly associated with relaxation and nighttime support. When integrated thoughtfully under medical oversight, such formulations align with palliative care goals of comfort, individualized support, and quality of life enhancement rather than symptom suppression alone.

References:

1. Abrams, Donald I., Joan F. Hilton, Roslyn J. Leiser, Starley B. Shade, Tarek A. Elbeik, Francesca T. Aweeka, Neal L. Benowitz, et al. “Short-Term Effects of Cannabinoids in Patients with HIV-1 Infection.” Annals of Internal Medicine 139, no. 4 (August 19, 2003): 258. https://doi.org/10.7326/0003-4819-139-4-200308190-00008
2. Bridgeman, Mary Barna, and Daniel T Abazia. “Medicinal Cannabis: History, Pharmacology, and Implications for the Acute Care Setting.” Pharmacy and Therapeutics 42, no. 3 (March 2017): 180. https://pmc.ncbi.nlm.nih.gov/articles/PMC5312634/
3. “Delta-9-Tetrahydrocannabinol May Palliate Altered Chemosensory Perception in Cancer Patients: Results of a Randomized, Double-Blind, Placebo-Controlled Pilot Trial.” Annals of Oncology 22, no. 9 (September 1, 2011): 2086–93. https://doi.org/10.1093/annonc/mdq727
4. Ebrahimi, Hossein, Abbas Mardani, Mohammad Hasan Basirinezhad, Azam Hamidzadeh, and Fatemeh Eskandari. “The Effects of Lavender and Chamomile Essential Oil Inhalation Aromatherapy on Depression, Anxiety and Stress in Older Community-Dwelling People: A Randomized Controlled Trial.” EXPLORE 18, no. 3 (January 2021). https://doi.org/10.1016/j.explore.2020.12.012
5. Groves, Melissa. “12 Science-Backed Benefits of Peppermint Tea and Extracts.” Healthline. Healthline Media, October 12, 2018. https://www.healthline.com/nutrition/peppermint-tea
6. Häuser, Winfried, Mary-Ann Fitzcharles, Lukas Radbruch, and Frank Petzke. “Cannabinoids in Pain Management and Palliative Medicine.” Deutsches Aerzteblatt Online, September 22, 2017. https://doi.org/10.3238/arztebl.2017.0627
7. Kemmner, Sarah F, Jennifer Dörfler, and Jutta Huebner. “Cannabinoids for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Oncological Therapy: A Systematic Review.” Journal of Cancer Survivorship, August 12, 2025. https://doi.org/10.1007/s11764-025-01876-4
8. Mersiades, Antony, Adrienne Kirby, Martin R Stockler, Annette Tognela, Ian N Olver, Rachael L Morton, Paul Haber, et al. “Cannabis Extract for Secondary Prevention of Chemotherapy-Induced Nausea and Vomiting: Results of a Phase II/III, Placebo-Controlled, Randomised Trial.” 41, no. 16_suppl (June 1, 2023): 12019–19. https://doi.org/10.1200/jco.2023.41.16_suppl.12019
9. Nikkhah Bodagh, Mehrnaz, Iradj Maleki, and Azita Hekmatdoost. “Ginger in Gastrointestinal Disorders: A Systematic Review of Clinical Trials.” Food Science & Nutrition 7, no. 1 (November 5, 2019): 96–108. https://doi.org/10.1002/fsn3.807
10. Troyer, James, and Kimberson Tanco. “Review of the Use of Medicinal Cannabis Products in Palliative Care.” Cancers 16, no. 7 (April 4, 2024): 1412–12. https://doi.org/10.3390/cancers16071412
11. Vigil, Jacob M., Marena A. Montera, Nathan S. Pentkowski, Jegason P. Diviant, Joaquin Orozco, Anthony L. Ortiz, Lawrence J. Rael, and Karin N. Westlund. “The Therapeutic Effectiveness of Full Spectrum Hemp Oil Using a Chronic Neuropathic Pain Model.” Life 10, no. 5 (May 18, 2020): 69. https://doi.org/10.3390/life10050069
12. Wang, Li, Patrick J. Hong, Curtis May, Yasir Rehman, Yvgeniy Oparin, Chris J. Hong, Brian Y. Hong, et al. “Medical Cannabis or Cannabinoids for Chronic Non-Cancer and Cancer Related Pain: A Systematic Review and Meta-Analysis of Randomised Clinical Trials.” BMJ 374 (September 9, 2021): n1034. https://doi.org/10.1136/bmj.n1034